micafungin + amphotericin B deoxycholate
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Candidiasis
Conditions
Candidiasis
Trial Timeline
Feb 1, 2013 → Dec 1, 2014
NCT ID
NCT00815516About micafungin + amphotericin B deoxycholate
micafungin + amphotericin B deoxycholate is a phase 3 stage product being developed by Astellas Pharma for Candidiasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00815516. Target conditions include Candidiasis.
What happened to similar drugs?
5 of 20 similar drugs in Candidiasis were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00815516 | Phase 3 | Terminated |
Competing Products
20 competing products in Candidiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 29 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 29 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 35 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 40 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 40 |
| FK463 | Astellas Pharma | Phase 2 | 35 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 40 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| L-743,872 | Merck | Pre-clinical | 26 |
| Caspofungin | Merck | Phase 2 | 35 |
| L-743,872 | Merck | Phase 2 | 27 |
| Caspofungin + Amphotericin B Deoxycholate | Merck | Phase 2 | 27 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 27 |
| Caspofungin + Normal Saline | Merck | Approved | 43 |
| caspofungin acetate | Merck | Phase 3 | 40 |